Creating a new treatment to block harmful immune responses in blood diseases
Official title: Development of a first-in-class complement inhibitor for treating complement-mediated hematologic diseases
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10990215 · Data updated 2026-11-12
This study is working on a new treatment to help people with blood disorders like PNH and AIHA by creating special therapies that can stop the body from destroying red blood cells too quickly, aiming to offer better options than what’s currently available.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 5, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $563,500 |
| NIH project number | 1R61HL171747-01A1 |
| Project ID | NIH-10990215 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with paroxysmal nocturnal hemoglobinuria (PNH) or autoimmune hemolytic anemia (AIHA).
✕Less likely to help
Patients with other types of anemia or blood disorders not related to complement activation may not benefit from this research.
What this research studies
This research focuses on developing a novel complement inhibitor aimed at treating hematologic diseases like paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). The approach involves creating and testing new nanobody-based therapies that can effectively inhibit excessive complement activation, which leads to the destruction of red blood cells. Patients may benefit from this research as it seeks to provide a more effective treatment option than currently available therapies. The research will involve both the development of these inhibitors and testing their effectiveness in preclinical models.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment for patients suffering from complement-mediated blood diseases.
How similar studies have gone: Previous research has shown promise in developing complement inhibitors, but this approach aims to create a first-in-class treatment that has not yet been tested.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Lin, Feng C — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Lin, Feng C
Related research
Other NIH-funded projects on the same topics.
-
First-in-class complement inhibitor for blood diseases that damage red blood cells
A new, targeted therapy being developed to help people with blood diseases like PNH and AIHA by blocking the immune system’s complement attack on red blood cells.
-
Mentored research training and professional development for kidney, urologic, and hematologic diseases
A program to help trainees in Philadelphia-area kidney, urologic, and blood disease research build skills, get mentoring, and prepare for future scientific careers.
-
A new targeted drug to block harmful complement activity in blood disorders
A novel nanobody drug designed to block the complement system to help people with PNH or autoimmune hemolytic anemia.
-
Training program for researchers in kidney, urologic, and blood diseases
This program is designed to help people training in kidney, urologic, and blood diseases become better researchers by offering mentorship, resources, and support to boost their skills and career opportunities.
-
Gene editing in bone marrow to treat blood disorders
This study is exploring a new way to use gene editing to treat blood disorders like sickle cell disease and β-thalassemia by making changes directly in the bone marrow, which could be safer and cheaper than current methods.
-
Romiplostim to help platelets grow after donor stem cell transplant
This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.